E-7766
- Generic Name
- E-7766
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04144140
- Locations
- 🇺🇸
University of Pittsburgh Medical Center and Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT04109092
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸UCLA, Santa Monica, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath